Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Ranolazine (Primary)
- Indications Coronary artery disease
- Focus Biomarker; Pharmacodynamics
- Acronyms RAND-CFR
- 10 Jun 2017 Biomarkers information updated
- 25 Aug 2016 Status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.